Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Other Operating Expenses (2018 - 2026)

Akebia Therapeutics has reported Other Operating Expenses over the past 8 years, most recently at $26.2 million for Q4 2025.

  • Quarterly Other Operating Expenses changed N/A to $26.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27.8 million through Dec 2025, up 7904.32% year-over-year, with the annual reading at -$524000.0 for FY2023, N/A changed from the prior year.
  • Other Operating Expenses was $26.2 million for Q4 2025 at Akebia Therapeutics, up from $578000.0 in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $35.1 million in Q2 2021 and troughed at -$524000.0 in Q2 2023.
  • The 5-year median for Other Operating Expenses is $579000.0 (2025), against an average of $5.5 million.
  • Year-over-year, Other Operating Expenses skyrocketed 6353.68% in 2021 and then crashed 62.14% in 2023.
  • A 5-year view of Other Operating Expenses shows it stood at $1.0 million in 2021, then plummeted by 56.37% to $449000.0 in 2022, then tumbled by 216.7% to -$524000.0 in 2023, then surged by 166.22% to $347000.0 in 2024, then skyrocketed by 7459.08% to $26.2 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Other Operating Expenses are $26.2 million (Q4 2025), $578000.0 (Q3 2025), and $580000.0 (Q2 2025).